Comparing Coherus Biosciences (NASDAQ:CHRS) and Cortexyme (NASDAQ:CRTX)

Share on StockTwits

Coherus Biosciences (NASDAQ:CHRS) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Institutional & Insider Ownership

99.2% of Coherus Biosciences shares are owned by institutional investors. 18.2% of Coherus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Coherus Biosciences and Cortexyme’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Coherus Biosciences N/A -2,573.23% -120.29%
Cortexyme N/A N/A N/A

Analyst Ratings

This is a summary of current recommendations and price targets for Coherus Biosciences and Cortexyme, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coherus Biosciences 0 0 6 0 3.00
Cortexyme 1 1 1 0 2.00

Coherus Biosciences presently has a consensus target price of $30.17, indicating a potential upside of 68.43%. Cortexyme has a consensus target price of $34.25, indicating a potential upside of 24.45%. Given Coherus Biosciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe Coherus Biosciences is more favorable than Cortexyme.

Valuation and Earnings

This table compares Coherus Biosciences and Cortexyme’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coherus Biosciences $1.56 million 796.07 -$209.34 million ($3.22) -5.56
Cortexyme N/A N/A -$12.48 million N/A N/A

Cortexyme has lower revenue, but higher earnings than Coherus Biosciences.

Summary

Coherus Biosciences beats Cortexyme on 6 of the 9 factors compared between the two stocks.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Coherus BioSciences, Inc. has collaboration and license agreements with Daiichi Sankyo Company, Limited; Baxalta Incorporated; Baxalta US Inc.; Baxalta GmbH; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Cortexyme Company Profile

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MKM Partners Lowers ADTRAN  Price Target to $17.00
MKM Partners Lowers ADTRAN Price Target to $17.00
Apple  PT Raised to $180.00 at Nomura
Apple PT Raised to $180.00 at Nomura
Advaxis  Lowered to “Hold” at ValuEngine
Advaxis Lowered to “Hold” at ValuEngine
Zacks Investment Research Upgrades Atlas Air Worldwide  to “Hold”
Zacks Investment Research Upgrades Atlas Air Worldwide to “Hold”
Apple  Raised to “Outperform” at Raymond James
Apple Raised to “Outperform” at Raymond James
Zacks Investment Research Lowers Agilysys  to Hold
Zacks Investment Research Lowers Agilysys to Hold


© 2006-2019 Ticker Report